Danish drugmaker Novo Nordisk has introduced its blockbuster diabetes treatment Ozempic in India, aiming to strengthen its position in the world’s most populous market.

The weekly injectable has been priced at Rs2,200 to start. Ozempic contains semaglutide—the same active ingredient used in Wegovy, which entered the Indian market in June as a weight-loss therapy.

Although formulated at a lower dosage than Wegovy, Ozempic is also widely used off-label for weight loss due to its appetite-suppressing effects.

Semaglutide and tirzepatide, the latter marketed by US-based Eli Lilly in India as Mounjaro, belong to the GLP-1 class of therapies. These drugs mimic gut hormones to regulate blood sugar, curb appetite, and prolong satiety.

India has about 25.4 crore people living with generalised o

See Full Page